BridgeBio Pharma Inc (BBIO)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$36.69

Buy

$39.00

arrow-up$0.04 (+0.10%)

Prices updated at 02 May 2025, 09:00 BST
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up1.52%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
-
CEO
Dr. Neil Kumar, PhD
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
730
Head office
3160 Porter Drive
Palo Alto
United States
94304
mobile
+1 650 391-9740
letter
-
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Dr. Thomas Trimarchi, PhD
Principal Financial Officer and President
0.64m0.45m-6.50m-
Dr. Charles J. Homcy,M.D.
Lead director
0.05m--1.12m-
Mr. Fred Hassan
Lead Independent Director
0.05m--0.60m-
Mr. James C. Momtazee
Independent Director
0.05m--0.60m-
Dr. Randal W. Scott,PhD
Independent Director
0.05m--0.60m-
Dr. Frank P. McCormick, D.Sc.,F.R.S.,PhD
Director
0.05m--1.10m-
Dr. Eric Aguiar, M.D.
Independent Director
0.05m--0.60m-
Mr. Ali J. Satvat
Independent Director
0.05m--0.60m-
Mr. Douglas A. Dachille
Independent Director
0.05m--0.60m-
Dr. Neil Kumar, PhD
Director; Chief Executive Officer of the Company and Eidos Therapeutics, Inc.
0.99m1.04m-15.58m-
Ms. Jennifer E. Cook
Independent Director
0.05m--0.60m-
Mr. Ronald J. Daniels
Independent Director
0.05m--0.60m-
Dr. Andrew W. Lo, PhD
Independent Director
0.05m--0.65m-
Dr. Hannah A. Valantine, M.D.
Independent Director
0.05m--0.60m-
Ms. Andrea John Ellis
Independent Director
0.05m--0.60m-
Ms. Maricel M. Apuli
Chief Accounting Officer
-----

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
KKR Genetic Disorder LP25,260,971--9250000-26.80307130 Apr 202513.37
Kohlberg Kravis Roberts & Co LP25,260,97118.56117--30 Apr 202513.30
Viking Global Investors LP25,120,9912.2308--30 Apr 202513.23
Vanguard Group Inc15,077,9150.007218790596.19105530 Apr 20257.94
BlackRock Inc13,709,6460.007618301366.445430 Apr 20257.22

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
30 Dec 2024-Mr. Ali J. Satvat16.68664,715119,553--
30 Dec 2024-Mr. Ali J. Satvat26.211,044,495159,404--
30 Dec 2024-Mr. Ali J. Satvat10.99875,92579,702--
30 Dec 2024-Mr. Ali J. Satvat-----
30 Dec 2024-Mr. Ali J. Satvat-----
30 Dec 2024-Mr. Ali J. Satvat-----
26 Dec 2024-Dr. Frank P. McCormick, D.Sc.--112,686--
24 Dec 2024-Dr. Neil Kumar, PhD--211,718--
24 Dec 2024-Dr. Neil Kumar, PhD--5,698,447--
10 Dec 2024-Dr. Neil Kumar, PhD--121,951--
10 Dec 2024-Dr. Brian C. Stephenson, PhD--42,683--
10 Dec 2024-Dr. Thomas Trimarchi, PhD--427,987--
19 Nov 2024-Dr. Neil Kumar, PhD22.39571,1464,899,318--
19 Nov 2024-Dr. Neil Kumar, PhD22.7642,6804,897,443--
19 Nov 2024-Dr. Brian C. Stephenson, PhD22.4193,13793,758--
16 Nov 2024-Dr. Neil Kumar, PhD--4,952,980--
16 Nov 2024-Dr. Neil Kumar, PhD--254,791--
16 Nov 2024-Dr. Neil Kumar, PhD--301,896--
16 Nov 2024-Dr. Neil Kumar, PhD--2,395--
16 Nov 2024-Dr. Neil Kumar, PhD23.72667,6714,924,832--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.